JAPAN FIRM SEEKS APPROVAL FOR COVID-19 PILL

Drugmaker Shionogi & Co has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday.

Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer and Merck.

In a statement, Shionogi said it was seeking conditional early approval of the drug after completing the Phase IIb part of a Phase II/III clinical trial in Japan and South Korea.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button